- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT04000061
Hjertesvikt-USB: Prediksjon og progresjon (HF-USB)
This retrospective cohort study is to identify triggers of heart failure (HF) development and drivers of HF progression as well as the underlying cardiac disease (phenotype) to identify patients at risk and predict the clinical course of the disease. Data of patients who were hospitalized during the years 2010-2023 with acute coronary syndrome (ACS) and/ or with acute heart failure (AHF) will be collected and analyzed. In a subgroup cohort efficacy and safety of digoxin in patients with acute heart failure triggered by tachyarrhythmia will be evaluated.
Studieoversikt
Status
Intervensjon / Behandling
Studietype
Registrering (Antatt)
Kontakter og plasseringer
Studiekontakt
- Navn: Christian Müller, Prof. Dr.
- Telefonnummer: 0041 6132 86 549
- E-post: Christian.mueller@usb.ch
Studer Kontakt Backup
- Navn: Fiona Nafaa, MD
- Telefonnummer: +41 61 32 87747
- E-post: fiona.nafaa@usb.ch
Studiesteder
-
-
-
Basel, Sveits, 4031
- Rekruttering
- Cardiology, University Hospital Basel
-
Ta kontakt med:
- Christian Mueller, Prof. Dr.
- Telefonnummer: +41 61 32 86 549
- E-post: Christian.mueller@usb.ch
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Prøvetakingsmetode
Studiepopulasjon
Patients that were hospitalized at the Universitätsspital Basel/ Switzerland with the diagnosis of ACS or AHF during the years 2010 - 2023
Beskrivelse
Inclusion Criteria:
- Patients hospitalized with a primary diagnosis of ACS
- Patients hospitalized with a primary or secondary diagnosis of AHF
Exclusion Criteria:
- Existence of a documented statement of the patient against the scientific use of clinical data
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Observasjonsmodeller: COHORT
- Tidsperspektiver: RETROSPECTIVE
Kohorter og intervensjoner
Gruppe / Kohort |
Intervensjon / Behandling |
|---|---|
|
acute coronary syndrome (ACS)
Outcome information (all-cause death, heart failure (HF) hospitalizations) of patients hospitalized with a primary diagnosis of ACS is analyzed. |
data generated by medical review include Medical history, Medications at presentation, during hospitalization and at discharge, New York Heart Association (NYHA) class, Killip class, Electrocardiographic (ECG) data, echocardiographic data, Interventions (Percutaneous Coronary Intervention (PCI), Coronary Artery Bypass Graft (CABG), Implantable Cardioverter Defibrillator (ICD) implantation, Cardiac Resynchronization Therapy (CRT) Implantation), Outcome Information: all-cause death, HF hospitalizations data generated by direct IT export include Anthropometric data (age, sex, height, weight), Vital signs, Laboratory data |
|
acute heart failure (AHF)
Outcome information (all-cause death, heart failure (HF) hospitalizations) of patients hospitalized with a primary or secondary diagnosis of AHF is analyzed. |
data generated by medical review include Medical history, Medications at presentation, during hospitalization and at discharge, New York Heart Association (NYHA) class, Killip class, Electrocardiographic (ECG) data, echocardiographic data, Interventions (Percutaneous Coronary Intervention (PCI), Coronary Artery Bypass Graft (CABG), Implantable Cardioverter Defibrillator (ICD) implantation, Cardiac Resynchronization Therapy (CRT) Implantation), Outcome Information: all-cause death, HF hospitalizations data generated by direct IT export include Anthropometric data (age, sex, height, weight), Vital signs, Laboratory data |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
number of all-cause death
Tidsramme: 1 to 8 years after hospitalization
|
number of all-cause death in patients hospitalized with ACS and AHF during the years 2010-2023. |
1 to 8 years after hospitalization
|
|
number of HF hospitalizations
Tidsramme: 1 to 8 years after hospitalization
|
number of new HF hospitalizations in patients hospitalized with ACS and AHF during the years 2010-2023 |
1 to 8 years after hospitalization
|
|
number of cardiovascular death
Tidsramme: 1 to 8 years after hospitalization
|
number of cardiovascular death in patients hospitalized with ACS and AHF |
1 to 8 years after hospitalization
|
|
number of cardiovascular hospitalizations
Tidsramme: 1 to 8 years after hospitalization
|
number of cardiovascular hospitalizations |
1 to 8 years after hospitalization
|
Samarbeidspartnere og etterforskere
Etterforskere
- Hovedetterforsker: Christian Müller, Prof. Dr., Cardiology University Hospital Basel
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- 2019-00956
- 2019 (U.S. NIH-stipend/kontrakt)
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .